Fraser Finance

The Landbanking Group is a private company focused on enhancing the investment in natural capital through an eco-tech platform. It unites scientists, builders, technology experts, and investors to facilitate payments and investments that support environmental sustainability. The platform offers account documents and trade certificates that verify ecosystem outcomes, thereby creating market access in various natural markets. This innovative approach enables businesses and investors to establish natural capital accounts, fostering a more sustainable and responsible approach to environmental resources.

Therapixel develops and commercializes AI-based software for breast cancer detection and characterization

PathoQuest SAS is a biotechnology company that specializes in advanced metagenomics for pathogen detection, having originated as a spin-off from Institut Pasteur. The company utilizes proprietary next-generation sequencing (NGS) technology, which combines innovative sample preparation with a comprehensive database of pathogen genomic information. This approach allows clinicians and biopharmaceutical professionals to enhance the detection of infectious agents in various biological samples. PathoQuest's Viral Safety testing service, aimed at biopharmaceutical companies, represents its first commercial application and has rapidly generated revenue from major industry players. The company's cloud-based bioinformatics platform and automated analysis pipeline further facilitate improved pathogen detection, making its solutions valuable for both clinical and biopharmaceutical quality assurance.

Incision is a developer of a medical education platform built to offer a standardized method of how to perform a procedure in practical steps and sub-steps.

Spearad runs a multi format platform for Addressable TV advertising. Our platform helps media owners to monetize content for all available screens. Spearad changes the way advertising is sold, delivered and measured in the new era of personally-targeted and IP based TV. Our technology allows all media players in the television, OTT/VOD and Audio business to fully benefit from the advantages of digital advertising while still maintaining the specifics of audio and television. The company was founded by industry leaders ensuring maximum market acceptance and high standing technological expertise. Spearad is operating worldwide and currently has subsidiaries in Germany, UK and the US.

PathoQuest SAS is a biotechnology company that specializes in advanced metagenomics for pathogen detection, having originated as a spin-off from Institut Pasteur. The company utilizes proprietary next-generation sequencing (NGS) technology, which combines innovative sample preparation with a comprehensive database of pathogen genomic information. This approach allows clinicians and biopharmaceutical professionals to enhance the detection of infectious agents in various biological samples. PathoQuest's Viral Safety testing service, aimed at biopharmaceutical companies, represents its first commercial application and has rapidly generated revenue from major industry players. The company's cloud-based bioinformatics platform and automated analysis pipeline further facilitate improved pathogen detection, making its solutions valuable for both clinical and biopharmaceutical quality assurance.

Lumeon Ltd. is a digital health company based in London, United Kingdom, specializing in care pathway management solutions for the healthcare sector. Founded in 2005 and formerly known as Qinec Ltd., Lumeon offers a cloud-based platform called Care Pathway Manager, which provides a comprehensive, real-time overview of the patient journey from referral to outcome. The company's services encompass business analysis, project management, configuration, data migration, training, and ongoing support. By focusing on the entire care pathway, Lumeon enables healthcare providers to unify clinical and administrative workflows, automate tasks, and achieve measurable healthcare outcomes. Its client base includes some of Europe's leading healthcare providers, such as BUPA, Nuffield Health, and HCA, reflecting the company's role in driving healthcare transformation.

Tessian’s mission is to secure the human layer. Using machine learning technology, Tessian automatically stops data breaches and security threats caused by human error - like data exfiltration, accidental data loss, business email compromise, and phishing attacks - with minimal disruption to employees' workflow. As a result, employees are empowered to do their best work, without security getting in their way. Founded in 2013, Tessian is backed by renowned investors like Sequoia, Accel, March Capital, and Balderton, and has offices in San Francisco and London.

Clinical Genomics is a privately held biotechnology company developing innovative products for colorectal cancer diagnosis and monitoring. With a broad intellectual property portfolio including more than 20 issued and pending patents, Clinical Genomics has developed and validated a sensitive and specific blood test for colorectal cancer recurrence monitoring that will be launched in the U.S. in 2016. This 2-gene test, which is based on methylated DNA from two genes, BCAT1 and IKZF1, is currently known by its project name GEMINI.

PathoQuest SAS is a biotechnology company that specializes in advanced metagenomics for pathogen detection, having originated as a spin-off from Institut Pasteur. The company utilizes proprietary next-generation sequencing (NGS) technology, which combines innovative sample preparation with a comprehensive database of pathogen genomic information. This approach allows clinicians and biopharmaceutical professionals to enhance the detection of infectious agents in various biological samples. PathoQuest's Viral Safety testing service, aimed at biopharmaceutical companies, represents its first commercial application and has rapidly generated revenue from major industry players. The company's cloud-based bioinformatics platform and automated analysis pipeline further facilitate improved pathogen detection, making its solutions valuable for both clinical and biopharmaceutical quality assurance.

Lumeon Ltd. is a digital health company based in London, United Kingdom, specializing in care pathway management solutions for the healthcare sector. Founded in 2005 and formerly known as Qinec Ltd., Lumeon offers a cloud-based platform called Care Pathway Manager, which provides a comprehensive, real-time overview of the patient journey from referral to outcome. The company's services encompass business analysis, project management, configuration, data migration, training, and ongoing support. By focusing on the entire care pathway, Lumeon enables healthcare providers to unify clinical and administrative workflows, automate tasks, and achieve measurable healthcare outcomes. Its client base includes some of Europe's leading healthcare providers, such as BUPA, Nuffield Health, and HCA, reflecting the company's role in driving healthcare transformation.

ExThera Medical, based in Martinez, Calif., is targeting the clinical treatment of blood-borne diseases including viremia and bacteremia, as well as the removal of harmful substances present in banked human blood. For example, the treatment of bacteremia, caused by S. aureus or MRSA (Methicillin-Resistant S. aureus) usually relies heavily on antibiotics. ExThera Medical’s Seraph® device uses the affinity of bacteria to immobilized heparin within the device, to bind the pathogen and lower its concentration in the bloodstream. Naturally-occurring heparin is a well-known anticoagulant that has many other useful biological properties making Seraph® a ‘biomimetic therapeutic device’. It can be an adjunct to anti-infective drugs by reducing the load and duration of infection, potentially preventing complications and the systemic inflammatory response that leads to organ failure. When no effective drugs are available Seraph may help patients recover by supplementing their own immune systems.

Tessian’s mission is to secure the human layer. Using machine learning technology, Tessian automatically stops data breaches and security threats caused by human error - like data exfiltration, accidental data loss, business email compromise, and phishing attacks - with minimal disruption to employees' workflow. As a result, employees are empowered to do their best work, without security getting in their way. Founded in 2013, Tessian is backed by renowned investors like Sequoia, Accel, March Capital, and Balderton, and has offices in San Francisco and London.

Lumeon Ltd. is a digital health company based in London, United Kingdom, specializing in care pathway management solutions for the healthcare sector. Founded in 2005 and formerly known as Qinec Ltd., Lumeon offers a cloud-based platform called Care Pathway Manager, which provides a comprehensive, real-time overview of the patient journey from referral to outcome. The company's services encompass business analysis, project management, configuration, data migration, training, and ongoing support. By focusing on the entire care pathway, Lumeon enables healthcare providers to unify clinical and administrative workflows, automate tasks, and achieve measurable healthcare outcomes. Its client base includes some of Europe's leading healthcare providers, such as BUPA, Nuffield Health, and HCA, reflecting the company's role in driving healthcare transformation.

F2G Ltd is a biotechnology company based in Manchester, United Kingdom, that specializes in developing innovative therapies for serious fungal diseases. Established in 1998, F2G focuses on its F3 series of antifungal compounds, particularly targeting challenging fungi such as Aspergillus and other filamentous molds that pose significant health risks. The company leverages its proprietary genomics technology, MycoBank, to identify critical gene targets in fungi, facilitating the creation of effective antifungal agents. Since its initial funding in 2002, F2G has expanded its research and development capabilities, enabling it to advance its patented compounds and contribute to addressing life-threatening fungal infections that affect individuals with compromised immune systems.

Pole Star, founded in 2002 and based in the United States and in France, is the pioneer and world leader in indoor location. Pole Star’s mission is to deliver high performance and complete range of indoor location services for venue owners and mobile solution providers covering over 100 million square feet of indoor areas worldwide.